CAS 179324-69-7
:Bortezomib
Description:
Bortezomib is a proteasome inhibitor primarily used in the treatment of multiple myeloma and certain types of lymphoma. It is a synthetic compound that belongs to the class of boronic acid derivatives. The chemical formula of Bortezomib is C19H25BoroN4O4, and it features a boron atom that plays a crucial role in its mechanism of action, which involves the inhibition of the proteasome, a cellular complex responsible for degrading ubiquitinated proteins. This inhibition leads to the accumulation of pro-apoptotic factors and cell cycle regulators, ultimately inducing apoptosis in cancer cells. Bortezomib is administered via intravenous or subcutaneous injection and is known for its side effects, which may include peripheral neuropathy, gastrointestinal issues, and hematological toxicities. Its pharmacokinetics involve rapid absorption and distribution, with a half-life that allows for effective dosing schedules. Overall, Bortezomib represents a significant advancement in targeted cancer therapy, showcasing the potential of small molecules in the treatment of hematological malignancies.
Formula:C19H25BN4O4
InChI:InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1
InChI key:InChIKey=GXJABQQUPOEUTA-RDJZCZTQSA-N
SMILES:[C@H](CC1=CC=CC=C1)(C(N[C@@H](CC(C)C)B(O)O)=O)NC(=O)C=2C=NC=CN2
Synonyms:- B-[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid
- Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-
- Boronic acid, [(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-
- Boronic acid, [3-methyl-1-[[1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-, [S-(R*,S*)]-
- Bortezomib for research
- Bortizomib
- Brotezamide
- Dpba
- Ldp 341
- Mg 341
- Mln 341
- N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
- N-[(1S)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-D-phenylalaninamide
- NSC 681239
- PS 341 (pharmaceutical)
- Ps 314
- Ps 341
- Radiciol
- Velcade
- See more synonyms
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 13 products.
Bortezomib
CAS:Formula:C19H25BN4O4Purity:>98.0%(HPLC)Color and Shape:White to Almost white powder to crystalMolecular weight:384.24Bortezomib, 98%
CAS:<p>Bortezomib, 179324-69-7, is a peptidic boronic acid analog and antineoplastic agent which turns off cell signaling pathways through 26S proteasome inhibition. Learn more.</p>Formula:C19H25BN4O4Purity:98%Color and Shape:Powder or crystals or crystalline powder, White to off-whiteMolecular weight:384.24Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-
CAS:Formula:C19H25BN4O4Purity:98%Color and Shape:SolidMolecular weight:384.2372Bortezomib
CAS:Formula:C19H25BN4O4Purity:≥ 98.0%Color and Shape:White to off-white powder or solidMolecular weight:384.24Bortezomib
CAS:<p>Bortezomib</p>Formula:C19H25BN4O4Purity:98% (nmr) (Typical Value in Batch COA)Color and Shape: white solidMolecular weight:384.24g/molBortezomib
CAS:<p>Bortezomib (LDP 341) is a 20S proteasome inhibitor (Ki=0.6 nM) that is reversible and selective.</p>Formula:C19H25BN4O4Purity:97.79% - >99.99%Color and Shape:Yellow SolidMolecular weight:384.24Bortezomib-D8 (Major)
CAS:Controlled Product<p>Applications Labelled Bortezomib, which the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells.d6-3%d7-10%d8-86%<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Nawrocki, S.T., et al: Cancer Research, 65, 11510 (2005)<br></p>Formula:C19H17D8BN4O4Color and Shape:Off-WhiteMolecular weight:392.29Bortezomib
CAS:Controlled Product<p>Stability Hygroscopic and Moisture Sensitive<br>Applications Bortezomib is the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells. Targets the ubiquitin-proteasome pathway.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Nawrocki, S.T., et al: Cancer Research, 65, 11510 (2005); Drahl C.: Chem. and Eng. News, 87, 41 (2009);<br></p>Formula:C19H25BN4O4Color and Shape:White To Off-WhiteMolecular weight:384.24Bortezomib - Bio-X ™
CAS:<p>Bortezomib is a selective and reversible inhibitor of the multicatalytic 26S proteasome. The inhibition of protein breakdown affects several metabolic pathways and leads to cell death. The compound is effective in treating t-cell lymphomas and multiple myeloma because it prevents the binding of myeloma cells to bone marrow stroma and inhibits osteoclast differentiation.</p>Formula:C19H25BN4O4Purity:Min. 95%Color and Shape:PowderMolecular weight:384.24 g/molBortezomib
CAS:<p>Selective and reversible inhibitor of the multicatalytic 26S proteasome. The inhibition of protein breakdown affects several metabolic pathways and leads to cell death. The compound is effective in treating multiple myeloma because it prevents the binding of myeloma cells to bone marrow stroma and inhibits osteoclast differentiation.</p>Formula:C19H25BN4O4Purity:Min. 95%Color and Shape:White PowderMolecular weight:384.24 g/mol
![Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]…](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb%2FDA0026XG.jpg&w=3840&q=75)
